help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lanfranco, F.
Right arrow Articles by Arvat, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lanfranco, F.
Right arrow Articles by Arvat, E.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 3 1385-1390
Copyright © 2004 by The Endocrine Society

Free Fatty Acids Exert an Inhibitory Effect on Adrenocorticotropin and Cortisol Secretion in Humans

Fabio Lanfranco, Roberta Giordano, Micaela Pellegrino, Laura Gianotti, Josefina Ramunni, Andreea Picu, Matteo Baldi, Ezio Ghigo and Emanuela Arvat

Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, I-10126 Turin, Italy

Address correspondence and requests for reprints to: Emanuela Arvat, M.D., Divisione di Endocrinologia e Malattie del Metabolismo, Dipartimento di Medicina Interna, Università di Torino, Corso Dogliotti 14, I-10126 Torino, Italy. E-mail: emanuela.arvat{at}unito.it.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Free fatty acid (FFA) administration stimulates the hypothalamic-pituitary-adrenal (HPA) axis in rats, suggesting that the HPA axis and lipolysis may be linked by a positive-feedback loop. To clarify the influence of FFA on the HPA axis in humans, we studied the effect of lipid load on both basal and stimulated ACTH and cortisol secretion in normal subjects. In six young female volunteers [(mean ± SEM) age, 24.4 ± 2.1 yr; body mass index, 23.1 ± 1.2 kg/m2), ACTH, cortisol, FFA, glucose, and insulin levels were measured every 30 min for 330 min during the following procedures: 1) iv saline infusion (from 0 to 330 min); 2) iv FFA infusion (Intralipid 10%, from 0 to 210 min) followed by saline infusion (from 210 to 330 min); 3) human CRH (hCRH) administration (2 µg/kg iv at 90 min) during saline infusion (from 0 to 330 min); and 4) hCRH administration during FFA infusion (Intralipid 10%, from 0 to 210 min, followed by saline infusion from 210 to 330 min). During saline infusion, ACTH and cortisol levels progressively declined. Lipid-heparin emulsion (LHE) infusion strikingly increased circulating FFA levels and, simultaneously, amplified the ACTH and cortisol decrease (P < 0.05). After LHE withdrawal, FFA decrease was associated with an increase (P < 0.05) in ACTH and cortisol levels (restored to baseline values within 60 min). The ACTH and cortisol responses to hCRH, however, were unaffected by LHE that, concomitantly, induced an increase (P < 0.05) in glucose but not in insulin levels. This study shows that an LHE-induced increase in FFA levels has an inhibitory effect on spontaneous ACTH and cortisol secretion in humans. Lipid load, however, does not affect the ACTH and cortisol responses to hCRH; this evidence would indicate that the negative influence of FFA on the HPA axis in humans takes place at the suprapituitary level.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
FREE FATTY ACIDS (FFA) are known to influence anterior pituitary function. GH secretion, for instance, is regulated by metabolic factors such as glucose (1, 2) and FFA (2, 3, 4). Because GH has a direct lipolytic effect (5), its inhibition by FFA has been hypothesized to reflect a negative-feedback mechanism on somatotroph function.

Among several factors modulating lipolysis, glucocorticoids have been shown to play a role; in fact, several studies demonstrated that the hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis is associated with the elevation of circulating FFA levels (6, 7). It had been hypothesized that the increase of circulating FFA levels could induce a suppression of HPA activity via a feedback mechanism. This hypothesis was tested in animals by Widmaier et al. (8), who, surprisingly, found a dose-related increase in ACTH and corticosterone levels after the infusion of Intralipid emulsion in rats; based on this evidence, the existence of a positive-feedback loop between FFA and the HPA axis was hypothesized. In fact, in vitro studies showed a direct stimulatory effect of FFA, especially long-chain unsaturated ones, on the adrenal gland (9, 10), although very high FFA concentrations have been shown to increase ACTH release from corticotroph cells (9). On the other hand, other authors reported a dual, dose-dependent effect of FFA on cortisol release from adrenal cells; in fact, oleic acid and linoleic acid were able to stimulate glucocorticoid production in the absence of adrenocorticotropic hormone despite high FFA concentrations, which inhibit ACTH action (11).

The influence, if any, of FFA on HPA axis activity in humans is still controversial. There is clear evidence that cortisol levels increase after a mixed meal; however, studies evaluating the effects of meal composition on the HPA axis showed that high-fat meals, as opposed to high-protein meals, do not modify spontaneous cortisol secretion (12, 13). Similarly, oral fat load did not modify the cortisol response to stress in normal subjects (14). On the other hand, the lipolytic effect exerted by glucocorticoids is well known in humans, and several pathophysiological conditions are connoted by both enhanced HPA axis activity and increased circulating FFA levels. These conditions include obesity (15, 16, 17), diabetes mellitus (18), fasting (19), and anorexia nervosa (17, 20).

Based on the foregoing, we aimed to clarify whether there is any influence of high FFA levels on the HPA axis in humans, suggesting the existence of a control of corticotroph function by lipids. To reach this goal, we studied the effect of an acute and high increase of circulating FFA levels induced by the infusion of a lipid-heparin emulsion (LHE) on both basal and stimulated ACTH and cortisol secretion in normal subjects.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Six young female volunteers [(mean ± SEM) age, 24.4 ± 2.1 yr; BMI, 23.1 ± 1.2 kg/m2) were studied in their early follicular phase in two consecutive menstrual cycles. All of the subjects gave their written informed consent to participate in the study. The study had been approved by the independent Ethical Committee of the University of Turin.

Each subject underwent the following tests: 1) iv saline infusion (500 ml of 0.9% NaCl solution) from 0 to 330 min; 2) iv 10% LHE infusion (350 ml Intralipid, Fresenius Kabi, Verona, Italy; together with 2500 U heparin, corresponding to 375.2 kcal) from 0 to 210 min, followed by saline infusion (200 ml of 0.9% NaCl solution) from 210 to 330 min; 3) iv human CRH (hCRH) administration (2 µg/kg at 90 min) during saline infusion from 0 to 330 min; and 4) iv hCRH administration (2 µg/kg at +90 min) during iv 10% LHE infusion from 0 to 210 min, followed by saline infusion (200 ml of 0.9% NaCl solution) from 210 to 330 min.

Intralipid is a suspension of soybean oil and glycerol; during Intralipid infusion, an increase of circulating FFA is generated from this suspension after the activation of lipoprotein lipase. To increase the lipoprotein lipase activity, heparin has been added to the suspension.

All tests were performed in the morning between 0830 and 0900 h, after an overnight fast and 30 min after an indwelling catheter was inserted in a forearm vein and kept patent by slow infusion of isotonic saline. All tests were performed in random order and at least 5 d apart.

Blood samples were taken every 30 min from 0 to 330 min. ACTH, cortisol, FFA, glucose, and insulin levels were measured at each time point. In test sessions 3 and 4, blood samples for ACTH and cortisol evaluation after hCRH administration were taken every 15 min from 90 to 210 min.

Plasma ACTH levels (pg/ml; 1 pg/ml x 0.22 = 1 pmol/liter) were measured in duplicate by immunoradiometric assay (Allegro HS-ACTH, Nichols Institute Diagnostics, San Juan Capistrano, CA). The sensitivity of the assay was 1 pg/ml. The inter- and intraassay coefficients of variation ranged from 6.9 to 8.9% and from 1.1 to 3.0%, respectively.

Serum cortisol levels (µg/dl; 1 µg/dl x 27.59 = 1 nmol/liter) were measured in duplicate by RIA (CORT-CTK 125 RIA, Sorin Biomedica, Saluggia, Italy). The sensitivity of the assay was 0.4 µg/dl. The inter- and intraassay coefficients of variation ranged from 6.6 to 7.5% and from 3.8 to 6.6%, respectively.

Plasma FFA levels (mEq/liter x 282 = 1 mg/liter) were measured by enzymatic analysis using the NEFA QUICK BMY kit (Roche Molecular Biochemicals, Yamanouchi, Tokyo, Japan).

Plasma glucose levels (mg/dl; 1 mg/dl x 0.05 = 1 mmol/liter) were measured by glucooxidase colorimetric method (GLUCOFIX, Menarini Diagnostici, Florence, Italy).

Serum insulin levels (mU/liter; 1 mU/liter x 7.17 = 1 pmol/liter) were measured in duplicate by immunoradiometric assay (INSIK-5, Sorin Biomedica). The sensitivity of the assay was 2.5 mU/liter. The inter- and intraassay coefficients of variation ranged from 6.2 to 10.8% and from 5.5 to 10.6%, respectively.

All samples from an individual subject were measured in the same assay.

The data are expressed as mean ± SEM of absolute values.

The statistical analysis was carried out using nonparametric ANOVA (Friedman test) and the Wilcoxon test, as appropriate.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
ACTH, cortisol, FFA, glucose, and insulin levels at baseline were similar in every session (Table 1Go and Figs. 1–4GoGoGoGo).


View this table:
[in this window]
[in a new window]
  		TABLE 1. FFA, ACTH, cortisol, glucose, and insulin basal and nadir or peak values in six normal women during the four test sessions

 


View larger version (13K):
[in this window]
[in a new window]
  		FIG. 1. Mean (±SEM) FFA levels during iv saline or LHE infusion (Intralipid 10%) in normal subjects. FFA, 1 mEq/liter x 282 = 1 mg/liter.

 


View larger version (20K):
[in this window]
[in a new window]
  		FIG. 2. Mean (±SEM) ACTH and cortisol levels during iv saline or LHE infusion (Intralipid 10%) in normal subjects. ACTH, 1 pg/ml x 0.22 = 1 pmol/liter; cortisol, 1 µg/dl x 27.59 = 1 nmol/liter.

 


View larger version (13K):
[in this window]
[in a new window]
  		FIG. 3. Mean (±SEM) glucose levels during iv saline or LHE infusion (Intralipid 10%) in normal subjects. Glucose, 1 mg/dl x 0.05 = 1 mmol/liter.

 


View larger version (20K):
[in this window]
[in a new window]
  		FIG. 4. Mean (±SEM) ACTH and cortisol levels after hCRH administration during iv saline or LHE infusion (Intralipid 10%) in normal subjects. ACTH, 1 pg/ml x 0.22 = 1 pmol/liter; cortisol, 1 µg/dl x 27.59 = 1 nmol/liter.

 
During saline infusion, both ACTH and cortisol levels showed a progressive decline (Table 1Go and Fig. 2Go). FFA, glucose, and insulin levels did not undergo significant variations during the saline session (Table 1Go and Figs. 1Go and 3Go).

LHE infusion led to a clear-cut increase in circulating FFA levels, which reached peak values at 210 min (P < 0.005) (Table 1Go and Fig. 1Go). This rise in FFA levels was associated with a significant decrease in ACTH levels (P < 0.05 vs. baseline), which reached nadir values between 90 and 210 min. This decrease was significantly higher than that recorded during saline infusion (P < 0.05 vs. time points 90, 120, 150, 180, and 210 min during saline). The FFA increase also induced a significant decrease in cortisol levels (P < 0.05 vs. baseline), which was more marked than during saline infusion (P < 0.05 vs. time points 90, 120, 150, 180, 210, and 240 min during saline) (Table 1Go and Fig. 2Go).

After withdrawal of LHE infusion, FFA levels showed a dramatic decrease (P < 0.05). This was associated with a progressive increase of ACTH and cortisol levels, which within 60 min reached values similar to those recorded during the saline session (Table 1Go and Fig. 2Go).

LHE infusion induced a significant (P < 0.05), progressive increase in glucose levels without any significant change in insulin secretion. Glucose levels remained stable after stopping the LHE infusion (Fig. 3Go).

hCRH induced the well-known, marked increase in both ACTH and cortisol levels (P < 0.05), which was not significantly modified by LHE infusion. Notably, ACTH and cortisol responses to hCRH during LHE infusion have been slightly delayed, but this change was not statistically different (Table 1Go and Fig. 4Go).

Side effects

No side effects were observed during LHE infusion. hCRH induced a transient facial flushing and tachycardia in five subjects.


   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
The results of this study demonstrate that a lipid load-induced increase of circulating FFA levels has an inhibitory influence on spontaneous ACTH and cortisol secretion in humans. However, the ACTH and cortisol responses to hCRH are not affected by the lipid load.

The existence of a relationship between the HPA axis and lipid metabolism is based on the well-known lipolytic action of glucocorticoids. In fact, the activation of this axis induces a clear increase of circulating FFA levels (6, 7). However, the influence, if any, of FFA on HPA activity is not well established.

Data from animal studies suggest a complex and not completely understood interplay between the HPA axis and FFA. A dose-related increase of circulating FFA concentrations elicited a stimulatory effect on both corticotroph and adrenal secretion in rats (8); these findings suggested a positive-feedback action of FFA on the HPA axis. However, a dual effect of lipids on adrenal activity also has been described (8, 10, 11, 21). In vitro studies have shown both an increase and a decrease of cortisol/corticosterone secretion from the adrenal gland, depending on the administered dose (8, 10, 11, 21); these findings suggested that circulating FFA could exert a dose-dependent, positive- or negative-feedback action on the HPA axis.

The data concerning the interplay between FFA and the HPA axis in humans are even scantier. Indirect evidence points toward a positive influence of FFA on the HPA axis, in agreement with animal data. In fact, several pathophysiological conditions, such as obesity (15, 16, 17), diabetes mellitus (18), fasting (19), and anorexia nervosa (17, 20) are connoted by concomitant enhancement of HPA axis activity and increased circulating FFA levels; theoretically, this HPA hyperactivity would, at least partially, reflect chronically elevated FFA levels.

In this context, our findings surprisingly show that an Intralipid-induced increase of circulating FFA concentrations exerts an inhibitory instead of stimulatory effect on the HPA axis in normal subjects; these findings do not support the hypothesis that exposure to high FFA levels stimulates the HPA axis and, on the contrary, suggest the existence of a negative feedback loop between FFA and HPA in humans. We chose an Intralipid dose equivalent to that used in many studies focused on the effect of FFA on GH secretion, which showed a clear inhibitory effect on somatotroph function (3, 4, 22). Indeed, this dose induced very supraphysiological FFA levels in our subjects, and therefore, we cannot exclude the concept that lower FFA levels could have a different impact (or no impact) on the ACTH and cortisol secretory pattern, as has been observed in animals (8). Moreover, a possible influence of heparin per se on HPA changes observed in our study cannot be definitely ruled out. In fact, controversial findings about the influence of heparin on adrenal function have been reported, showing either inhibiting effects or no effects on it (23, 24, 25).

Regarding the physiological relevance of the effect of LHE-induced FFA concentrations on the HPA axis in our study, the inhibitory influence exerted by pharmacological FFA levels does not allow us to state that a physiological control of HPA exerted by circulating FFA levels is operative. However, our results probably allow us to definitely rule out the possibility that FFA have a positive influence on HPA in humans. Thus, chronically elevated FFA levels in obesity (15, 16, 17), diabetes mellitus (18), fasting (19), and anorexia nervosa (17, 20) are unlikely to explain the HPA hyperactivation that connotes these pathological conditions.

The lack of influence of the lipid load on the ACTH and cortisol response to hCRH allows some speculation about the site where FFA inhibitory effect could take place. In fact, because the corticotroph response to hCRH is unchanged during exposure to high FFA levels, an action at the hypothalamic level can be hypothesized. Direct evidence supporting a FFA action on hypothalamic neurohormones and neurotransmitters mainly involved in the control of corticotroph function is, to our knowledge, lacking. An action of FFA at the pituitary level has been suggested by some authors who, however, found a stimulatory effect of high FFA concentrations only upon ACTH secretion from rat pituitary in vitro (9). A stimulatory role of FFA on corticosterone secretion as a result of a direct action of lipids on the adrenal glands, as well as the influence of FFA on peripheral glucocorticoid metabolism, has also been reported (10, 23, 24, 25). These data could reflect peripheral actions of FFA that, however, seem to be overridden by a major inhibitory influence taking place at a suprapituitary level, at least in humans.

A possible FFA action at the hypothalamic or suprahypothalamic level is suggested by the evidence that FFA possess an electrophysiological effect on the central nervous system and that FFA are taken up by central nervous system cells (26, 27). Moreover, this hypothesis fits well with other evidence indicating that metabolic fuels, including FFA, play a major role in the regulation of other neurohormones, e.g. GnRH and somatostatin (2, 4, 28, 29). At present, to our knowledge, there is no evidence definitely supporting CRH and/or arginine vasopressin modulation by FFA. On the other hand, the absence of the effect of an Intralipid-induced FFA increase on HPA response to hCRH is in agreement with a CRH-mediated mechanism, whereas some change in the corticotroph response to exogenous hCRH could be expected, assuming that FFA may have an inhibiting effect on endogenous arginine vasopressin release (30). Regarding the possibility that FFA may modulate neuropeptides and/or metabolites involved in energy balance, it has been shown that ghrelin, a new gastric hormone mainly involved in metabolic processes, also shows a stimulatory effect on the HPA axis. Some studies both in animals and humans demonstrated that the increase in circulating FFA levels induced by a fat load reduced circulating ghrelin levels (31, 32), although these data have not been confirmed by other studies (our unpublished results, and Ref. 33); thus, a possible involvement of ghrelin in the modulation of HPA function exerted by FFA cannot be excluded. Moreover, changes in glucose levels are known to influence the HPA axis. Hypoglycemia is a well-known stimulus of HPA function, whereas evidence indicating an inhibiting influence of glucose load on the HPA axis in humans is controversial (34, 35). A previous study in rats showed that Intralipid administration was followed by an increase in plasma glucose levels, which could theoretically account for the modulation of ACTH and corticosterone secretion observed in that study (8). The slight but significant increase in glucose levels under lipid load observed in our study could, theoretically, partially explain our findings. However, it must be noted that the glucose increase in the present study was clearly lower than that recorded after the administration of glucagon, which is a well-known stimulus of ACTH and cortisol secretion (36).

In conclusion, this study shows that the increase in circulating FFA levels induced by lipid load has an inhibitory effect on spontaneous ACTH and cortisol secretion in humans. Lipid load, however, does not affect the ACTH and cortisol responses to hCRH; this evidence would indicate that the negative influence of FFA on the HPA axis in humans takes place at the suprapituitary level.


   Acknowledgments
 
We thank Professor F. Camanni for his support of this study as well as Dr. A. Bertagna, A. Barberis, and M. Talliano for their skillful technical assistance.


   Footnotes
 
This work was supported by the University of Turin and the Foundation for the Study of Endocrinological and Metabolic Diseases.

Abbreviations: FFA, Free fatty acid(s); hCRH, human CRH; HPA, hypothalamic-pituitary-adrenal; LHE, lipid-heparin emulsion.

Received July 2, 2003.

Accepted December 4, 2003.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Masuda A, Shibasaki T, Nakahara M, Imaki T, Kiyosawa Y, Jibiki K, Demura H, Shizume K, Ling N 1985 The effect of glucose on growth hormone (GH)-releasing hormone-mediated GH secretion in man. J Clin Endocrinol Metab 60:523–526[Abstract]
  2. Imaki T, Shibasaki T, Masuda A, Hotta M, Yamauchi N, Demura H, Shizume K, Wakabayashi I, Ling N 1986 The effect of glucose and free fatty acids on growth hormone (GH)-releasing factor-mediated GH secretion in rats. Endocrinology 118:2390–2394[Abstract]
  3. Imaki T, Shibasaki T, Shizume K, Masuda A, Hotta M, Kiyosawa Y, Jibiki K, Demura H, Tsushima T, Ling N 1985 The effect of free fatty acids on growth hormone (GH)-releasing hormone-mediated GH secretion in man. J Clin Endocrinol Metab 60:290–293[Abstract]
  4. Maccario M, Procopio M, Loche S, Cappa M, Martina V, Camanni F, Ghigo E 1994 Interaction of free fatty acids and arginine on growth hormone secretion in man. Metabolism 43:223–226[CrossRef][Medline]
  5. Ho KK, O’Sullivan AJ, Hoffman DM 1996 Metabolic actions of growth hormone in man. Endocr J 43:S57–S63
  6. Bjorntorp P 1992 Neuroendocrine perturbations as a cause of insulin resistance. Diabetes Metab Res Rev 15:427–441[CrossRef]
  7. Ottosson M, Vikman-Adolfsson K, Enerback S, Olivecrona G, Bjorntorp P 1994 The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 79:820–825[Abstract]
  8. Widmaier EP, Rosen K, Abbott B 1992 Free fatty acids activate the hypothalamic-pituitary-adrenocortical axis in rats. Endocrinology 131:2313–2318[Abstract]
  9. Widmaier EP, Margenthaler J, Sarel I 1995 Regulation of pituitary-adrenocortical activity by free fatty acids in vivo and in vitro. Prostaglandins Leukot Essent Fatty Acids 52:179–183[CrossRef][Medline]
  10. Sarel I, Widmaier EP 1995 Stimulation of steroidogenesis in cultured rat adrenocortical cells by unsaturated fatty acids. Am J Physiol 268:R1484–R1490
  11. Matthys LA, Widmaier EP 1998 Fatty acids inhibit adrenocorticotropin- induced adrenal steroidogenesis. Horm Metab Res 30:80–83[Medline]
  12. Slag MF, Ahmad M, Gannon MC, Nuttall FO 1981 Meal stimulation of cortisol secretion: a protein induced effect. Metabolism 30:1104–1108[CrossRef][Medline]
  13. Ishizuka B, Quigley ME, Yen SSC 1983 Pituitary hormone release in response to food ingestion: evidence for neuroendocrine signals from gut to brain. J Clin Endocrinol Metab 57:1111–1116[Abstract]
  14. Gonzalez-Bono E, Rohleder N, Hellhammer DH, Salvador A, Kirschbaum C 2002 Glucose but not protein or fat load amplifies the cortisol response to psychosocial stress. Horm Behav 41:328–333[CrossRef][Medline]
  15. Bjorntorp P 1997 Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 13:795–803[CrossRef][Medline]
  16. Pasquali R 1998 Is the hypothalamic-pituitary-adrenal axis really hyperactivated in visceral obesity? J Endocrinol Invest 21:268–271[Medline]
  17. Douyon L, Schteingart DE 2002 Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am 31:173–189[CrossRef][Medline]
  18. Alrefai H, Allababidi H, Levy S, Levy J 2002 The endocrine system in diabetes mellitus. Endocrine 18:105–119[CrossRef][Medline]
  19. Akana SF, Strack AM, Hanson ES, Dallman MF 1994 Regulation of activity in the hypothalamo-pituitary-adrenal axis is integral to a larger hypothalamic system that determines caloric flow. Endocrinology 135:1125–1134[Abstract]
  20. Stoving RK, Hangaard J, Hansen-Nord M, Hagen C 1999 A review of endocrine changes in anorexia nervosa. J Psychiatr Res 33:139–152[CrossRef][Medline]
  21. Goodfriend TL, Ball DL, Elliott ME, Morrison AR, Evenson MA 1991 Fatty acids are potential endogenous regulators of aldosterone secretion. Endocrinology 128:2511–2519[Abstract]
  22. Casanueva FF, Villanueva L, Dieguez C, Diaz Y, Cabranes JA, Szoke B, Scanlon MF, Schally AV, Fernandez-Cruz A 1987 Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. J Clin Endocrinol Metab 65:634–642[Abstract]
  23. Kloppenborg PW, Casparie AF, Benraad TJ, Majoor CL 1975 Inhibition of adrenal function in man by heparin or heparinoid Ro 1–8307. Acta Med Scand 197:99–108[Medline]
  24. Jokay I, Karczag E, Kelemenics K, Foldes I 1979 Inhibition of cortisone action in mice by heparin. Endokrinologie 73:199–208[Medline]
  25. O’Kelly R, Magee F, McKenna TJ 1983 Routine heparin therapy inhibits adrenal aldosterone production. J Clin Endocrinol Metab 56:108–112[Abstract]
  26. Dhopeshwarkar GA, Mead JF 1969 Fatty acid uptake by the brain. II. Incorporation of [I-14C] palmitic acid into the adult rat brain. Biochim Biophys Acta 187:461–467[Medline]
  27. Love JA, Saum WR, McGee Jr R 1985 The effects of exposure to exogenous fatty acids and membrane fatty acid modification on the electrical properties of NG108–15 cells. Cell Mol Neurobiol 5:333–352[CrossRef][Medline]
  28. Archer ZA, Rhind SM, Findlay PA, Kyle CE, Thomas L, Marie M, Adam CL 2002 Contrasting effects of different levels of food intake and adiposity on LH secretion and hypothalamic gene expression in sheep. J Endocrinol 175: 383–393
  29. Senaris RM, Lewis MD, Lago F, Dominguez F, Scanlon MF, Dieguez C 1993 Effects of free fatty acids on somatostatin secretion, content and mRNA levels in cortical and hypothalamic fetal rat neurones in monolayer culture. J Mol Endocrinol 10:207–214[Abstract]
  30. Torpy DJ, Grice JE, Hockings GI, Walters MM, Crosbie GV, Jackson RV 1994 Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans. J Clin Endocrinol Metab 79:140–144[Abstract]
  31. Lee HM, Wang G, Englander EW, Kojima M, Greeley Jr GH 2002 Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 143:185–190[Abstract/Free Full Text]
  32. Monteleone P, Bencivenga R, Longobardi N, Serritella C, Maj M 2003 Differential responses of circulating ghrelin to high-fat or high-carbohydrate meal in healthy women. J Clin Endocrinol Metab 88:5510–5514[Abstract/Free Full Text]
  33. Mohlig M, Spranger J, Otto B, Ristow M, Tschop M, Pfeiffer AF 2002 Euglycemic hyperinsulinemia, but not lipid infusion, decreases circulating ghrelin levels in humans. J Endocrinol Invest 25:RC36–RC38
  34. Fish HR, Chernow B, O’Brian JT 1986 Endocrine and neurophysiologic responses of the pituitary to insulin-induced hypoglycemia: a review. Metabolism 35:763–780[CrossRef][Medline]
  35. Fernandez-Real JM, Ricart W, Casamitjana R 1997 Lower cortisol levels after oral glucose in subjects with insulin resistance and abdominal obesity. Clin Endocrinol (Oxf) 47:583–588[CrossRef][Medline]
  36. Arvat E, Maccagno B, Ramunni J, Maccario M, Giordano R, Broglio F, Camanni F, Ghigo E 2000 Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans. Eur J Endocrinol 143:99–104[Abstract]



This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
F. Lanfranco, L. Gianotti, A. Picu, R. Giordano, G. A. Daga, V. Mondelli, G. Malfi, S. Fassino, E. Ghigo, and E. Arvat
Effects of free fatty acids on ACTH and cortisol secretion in anorexia nervosa.
Eur. J. Endocrinol., May 1, 2006; 154(5): 731 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
P. Kok, S. W. Kok, M. M. Buijs, J. J. M. Westenberg, F. Roelfsema, M. Frolich, M. P. M. Stokkel, A. E. Meinders, and H. Pijl
Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment
Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E848 - E856.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lanfranco, F.
Right arrow Articles by Arvat, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lanfranco, F.
Right arrow Articles by Arvat, E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals